流式细胞术细胞因子谱检测在脓毒症诊断及死亡风险评估中的临床应用

马晋, 杨浩, 孙昌瑞, 雷雨, 吴春香

PDF(2018 KB)
PDF(2018 KB)
重庆医科大学学报 ›› 2024, Vol. 49 ›› Issue (12) : 1600-1607. DOI: 10.13406/j.cnki.cyxb.003678
临床研究

流式细胞术细胞因子谱检测在脓毒症诊断及死亡风险评估中的临床应用

作者信息 +

Clinical application of flow cytometric cytokine profiling in diagnosis of sepsis and assessment of mortality risk

Author information +
History +

摘要

目的 研究流式细胞术细胞珠阵列(cytometric bead array,CBA)法检测脓毒症患者人细胞因子谱表达水平,探讨并比较各细胞因子在脓毒症患者早期诊断及预测死亡风险中的临床应用价值。 方法 纳入256例ICU脓毒症患者,99例健康体检者和99例ICU非脓毒症患者,流式细胞术CBA法检测入组人群入院当天血浆IL-2、IL-4、IL-6、IL-10、TNF-α和IFN-γ的水平。Spearman及R语言Mantel检验分别用于常规相关性分析和指标集合间的相关性分析,构建受试者工作特征曲线(receiver operating characteristic,ROC)曲线,评估并比较人细胞因子谱中各细胞因子对脓毒症患者早期诊断及预估死亡风险的应用价值。 结果 脓毒症患者血浆人细胞因子谱中IL-6、IL-10水平明显高于健康对照及ICU非脓毒症患者。IL-6的早期脓毒症诊断ROC曲线下面积(area under curve,AUC)为0.868(P<0.000 1,95%CI=0.835~0.901),IL-10为0.831(P<0.000 1,95%CI=0.793~0.869)。Mantel检验指标集合间的相关性分析显示:在脓毒症患者死亡组中,IL-6与CRP呈显著相关性(r=0.101,P=0.001),IL-10与NEUT呈显著相关性(r=0.132,P=0.001)。人细胞因子谱中的各细胞因子预测28 d死亡率的AUC均低于0.70。 结论 使用流式细胞术CBA法检测人细胞因子在脓毒症早期诊断中表现出不同的效力。IL-6和IL-10能为脓毒症的早期临床诊断提供证据,但在预估死亡风险方面与其他因子效力相当。

Abstract

Objective To investigate the cytometric bead array(CBA) method in measuring the expression levels of human cytokine profiles in patients with sepsis,and to explore the clinical application value of different cytokines in the early diagnosis of sepsis and the prediction of mortality risk. Methods This study was conducted among 256 sepsis patients admitted to the intensive care unit (ICU),99 healthy individuals who underwent physical examination,and 99 non-sepsis patients admitted to the ICU,and the CBA method was used to measure the plasma levels of interleukin-2(IL-2),interleukin-4 (IL-4),interleukin-6(IL-6),interleukin-10 (IL-10),tumor necrosis factor-α(TNF-α),and interferon gamma(IFN-γ). The Spearman and Mantel tests in R language were used for the routine correlation analysis and the correlation analysis between indicator sets,and the receiver operating characteristic(ROC) curve was plotted to assess the application value of each cytokine in the human cytokine profile in the early diagnosis of sepsis patients and the prediction of mortality risk. Results The sepsis patients had significantly higher plasma levels of IL-6 and IL-10 in the human cytokine profile than the healthy controls and the non-sepsis patients admitted to the ICU. IL-6 had an area under the ROC curve(AUC) of 0.868(95%CI=0.835-0.901,P<0.000 1) in the early diagnosis of sepsis,while IL-10 had an AUC of 0.831(95%CI= 0.793-0.869,P<0.000 1). The correlation analysis of the indicator sets using the Mantel test showed a significant correlation between IL-6 and C-reactive protein in the sepsis mortality group(r=0.101,P=0.001),as well as a significant correlation between IL-10 and neutrophil count(r=0.132,P=0.001). All cytokines in the human cytokine profile had an AUC of <0.70 in predicting 28-day mortality rate. Conclusion Human cytokines measured by the CBA method have varying degrees of efficacy in the early diagnosis of sepsis. While IL-6 and IL-10 can offer valuable evidence for the early clinical diagnosis of sepsis,they have comparable efficacy to other cytokines in predicting mortality risk

关键词

细胞因子谱 / 脓毒症预后 / 白介素-6 / 白介素-10 / 生物标志物

Key words

cytokine profile / septic prognosis / interleukin-6 / interleukin-10 / biomarkers

中图分类号

R473.72

引用本文

导出引用
马晋 , 杨浩 , 孙昌瑞 , . 流式细胞术细胞因子谱检测在脓毒症诊断及死亡风险评估中的临床应用. 重庆医科大学学报. 2024, 49(12): 1600-1607 https://doi.org/10.13406/j.cnki.cyxb.003678
Ma Jin, Yang Hao, Sun Changrui, et al. Clinical application of flow cytometric cytokine profiling in diagnosis of sepsis and assessment of mortality risk[J]. Journal of Chongqing Medical University. 2024, 49(12): 1600-1607 https://doi.org/10.13406/j.cnki.cyxb.003678

参考文献

1
Singer M Deutschman CS Seymour CW,et al. The third international consensus definitions for sepsis and septic shock(sepsis-3)[J]. JAMA2016315(8):801-810.
2
Seymour CW Liu VX Iwashyna TJ,et al. Assessment of clinical criteria for sepsis:for the third international consensus definitions for sepsis and septic shock(sepsis-3)[J]. JAMA2016315(8):762-774.
3
Hotchkiss RS Moldawer LL Opal SM,et al. Sepsis and septic shock[J]. Nat Rev Dis Primers20162:16045.
4
Cecconi M Evans L Levy M,et al. Sepsis and septic shock[J]. Lancet2018392(10141):75-87.
5
Fleischmann-Struzek C Mellhammar L Rose N,et al. Incidence and mortality of hospital- and ICU-treated sepsis:results from an updated and expanded systematic review and meta-analysis[J]. Intensive Care Med202046(8):1552-1562.
6
Rudd KE Johnson SC Agesa KM,et al. Global,regional,and national sepsis incidence and mortality,1990-2017:analysis for the global burden of disease study[J]. Lancet2020395(10219):200-211.
7
Goodman CW Brett AS. Gabapentin and pregabalin for pain - is increased prescribing a cause for concern?[J]. N Engl J Med2017377(5):411-414.
8
Chen Y Ma XD Kang XH,et al. Association of annual hospital septic shock case volume and hospital mortality[J]. Crit Care202226(1):161.
9
Evans L Rhodes A Alhazzani W,et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med202147(11):1181-1247.
10
Peri AM Harris PNA Paterson DL. Culture-independent detection systems for bloodstream infection[J]. Clin Microbiol Infect202228(2):195-201.
11
Ferrer R Martin-Loeches I Phillips G,et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour:results from a guideline-based performance improvement program[J]. Crit Care Med201442(8):1749-1755.
12
Song J Park DW Moon S,et al. Diagnostic and prognostic value of interleukin-6,pentraxin 3,and procalcitonin levels among sepsis and septic shock patients:a prospective controlled study according to the sepsis-3 definitions[J]. BMC Infect Dis201919(1):968.
13
Romagnoli C Frezza S Cingolani A,et al. Plasma levels of interleukin-6 and interleukin-10 in preterm neonates evaluated for sepsis[J]. Eur J Pediatr2001160(6):345-350.
14
Xie ZH Lin B Jia XJ,et al. Enhanced IL-10 inhibits proliferation and promotes apoptosis of HUVECs through STAT3 signaling pathway in sepsis[J]. Histol Histopathol202136(11):1179-1187.
15
Li L Chen L Lin F,et al. Study of the expression of inflammatory factors IL-4,IL-6,IL-10,and IL-17 in liver failure complicated by coagulation dysfunction and sepsis[J]. J Inflamm Res202114:1447-1453.
16
Wu HP Wu CL Chen CK,et al. The interleukin-4 expression in patients with severe sepsis[J]. J Crit Care200823(4):519-524.
17
Feng MC Sun TT Zhao YX,et al. Detection of serum interleukin-6/10/18 levels in sepsis and its clinical significance[J]. J Clin Lab Anal201630(6):1037-1043.
18
Gogos CA Drosou E Bassaris HP,et al. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis:a marker for prognosis and future therapeutic options[J]. J Infect Dis2000181(1):176-180.
19
Young SH Antonini JM Roberts JR,et al. Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models[J]. J Immunol Methods2008331(1/2):59-68.
20
Zhang YY Li BR Ning BT. Evaluating IL-6 and IL-10 as rapid diagnostic tools for Gram-negative bacteria and as disease severity predictors in pediatric sepsis patients in the intensive care unit[J]. Front Immunol202213:1043968.
21
Mehra S Tiwari AK Aggarwal G,et al. Diagnostic value of different interleukins and procalcitonin in critically ill patients admitted with suspected sepsis[J]. Indian J Pathol Microbiol202265(1):111-116.
22
Xiang WQ Li L Wang BH,et al. Profiles and predictive value of cytokines in children with human metapneumovirus pneumonia[J]. Virol J202219(1):214.
23
Tang YM Liao C Xu XJ,et al. Th1/Th2 cytokine profiles in G+/G- bacteremia in pediatric hematology/oncology patients[J]. Pediatr Blood Cancer201258(1):50-54
24
Yang Y Lundqvist A. Immunomodulatory effects of IL-2 and IL-15;implications for cancer immunotherapy[J]. Cancers202012(12):3586.
25
Molano Franco D Arevalo-Rodriguez I Roqué I Figuls M,et al. Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults[J]. Cochrane Database Syst Rev20194(4):CD011811.
26
Kishimoto T. IL-6:from its discovery to clinical applications[J]. Int Immunol201022(5):347-352.
27
Kang SJ Kishimoto T. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms[J]. Exp Mol Med202153(7):1116-1123.
28
Cook EB Stahl JL Lowe L,et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry:allergics vs. non-allergics[J]. J Immunol Methods2001254(1/2):109-118.
29
Propper DJ Balkwill FR. Harnessing cytokines and chemokines for cancer therapy[J]. Nat Rev Clin Oncol202219(4):237-253.
30
Alspach E Lussier DM Schreiber RD. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity[J]. Cold Spring Harb Perspect Biol201911(3):a028480.
31
Romero CR Herzig DS Etogo A,et al. The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis[J]. J Leukoc Biol201088(4):725-735.
32
Saraiva M Vieira P O’Garra A. Biology and therapeutic potential of interleukin-10[J]. J Exp Med2020217(1):e20190418.
33
Bozza FA Salluh JI Japiassu AM,et al. Cytokine profiles as markers of disease severity in sepsis:a multiplex analysis[J]. Crit Care200711(2):R49.
34
Liu D Huang SY Sun JH,et al. Sepsis-induced immunosuppression:mechanisms,diagnosis and current treatment options[J]. Mil Med Res20229(1):56.
35
Zhu JF. T helper 2(Th2) cell differentiation,type 2 innate lymphoid cell(ILC2) development and regulation of interleukin-4(IL-4) and IL-13 production[J]. Cytokine201575(1):14-24.

基金

四川省科技计划重点研发资助项目(2022YFS0238)

评论

PDF(2018 KB)

Accesses

Citation

Detail

段落导航
相关文章

/